Experimental models of Duchenne Muscular Dystrophy: Relationship with cardiovascular disease

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 2, 2010, Pages 265-277

  Ameen, Venus ^a   Robson, Lesley G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiomyopathy; Muscular dystrophy

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATALUREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; GENTAMICIN; NATRIURETIC FACTOR; PARVOVIRUS VECTOR; PIRFENIDONE; PROTEINASE; SILDENAFIL; TROPONIN; UTROPHIN;

CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAT; CAUSE OF DEATH; CELL DEATH; CELL THERAPY; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; DOG; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENGRAFTMENT; ENZYME ACTIVATION; EXPERIMENTAL MODEL; GENE THERAPY; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; MUSCULOSKELETAL FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RADIOISOTOPE VENTRICULOGRAPHY; RESPIRATORY CARE; RESPIRATORY FAILURE; REVIEW; SARCOLEMMA;

EID: 84855494224     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010265     Document Type: Review

References (101)

1. Emery A. Duchenne muscular dystrophy or Meryon's disease. Lancet 2001; 357: 1529.
2. Emery AE. Population frequencies of inherited neuromusculardiseases--a world survey. Neuromuscul Disord 1991; 1: 19-29.
3. Hoffman EP, Kunkel LM. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 1989; 2: 1019-29.
4. Fayssoil A, Nardi O, Orlikowski D, Annane D. Cardiomyopathy inDuchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail Rev 2010; 15: 103-7.
5. Finsterer J, Stollberger C. Cardiac involvement in Becker musculardystrophy. Can J Cardiol 2008; 24: 786-92.
6. van Bockel EA, Lind JS, Zijlstra JG, et al. Cardiac assessment ofpatients with late stage Duchenne muscular dystrophy. Neth Heart J2009; 17: 232-7.
7. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003; 99: 1-19.
8. Toussaint M, Steens M, Wasteels G, Soudon P. Diurnal ventilationvia mouthpiece: survival in end-stage Duchenne patients. EurRespir J 2006; 28: 549-55.
9. Yasuma F, Konagaya M, Sakai M, Kuru S, Kawamura T. A newlease on life for patients with Duchenne muscular dystrophy in Japan. Am J Med 2004; 117: 363.
10. Oldfors A, Eriksson BO, Kyllerman M, Martinsson T, WahlstromJ. Dilated cardiomyopathy and the dystrophin gene: an illustratedreview. Br Heart J 1994; 72: 344-8.
11. Woolf PJ, Lu S, Cornford-Nairn R, et al. Alterations in dihydropyridinereceptors in dystrophin-deficient cardiac muscle. Am JPhysiol Heart Circ Physiol 2006; 290: H2439-H45.
12. Williams IA, Allen DG. Intracellular calcium handling in ventricularmyocytes from mdx mice. Am J Physiol Heart Circ Physiol2007; 292: H846-H55.
13. Constantin B, Sebille S, Cognard C. New insights in the regulationof calcium transfers by muscle dystrophin-based cytoskeleton: implicationsin DMD. J Muscle Res Cell Motil 2006; 27: 375-86.
14. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty JM, Jr. Preloadinduces troponin I degradation independently of myocardial ischemia. Circulation 2001; 103: 2035-7.
15. Gao WD, Atar D, Liu Y, Perez NG, Murphy AM, Marban E. Roleof troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997; 80: 393-9.
16. Raymackers JM, Debaix H, Colson-Van SM, et al. Consequence ofparvalbumin deficiency in the mdx mouse: histological, biochemicaland mechanical phenotype of a new double mutant. NeuromusculDisord 2003; 13: 376-87.
17. Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase (CK)and pyruvate-kinase (PK) activities in Duchenne (DMD) as comparedwith Becker (BMD) muscular dystrophy. J Neurol Sci 1991;102: 190-6.
18. Fanchaouy M, Polakova E, Jung C, Ogrodnik J, Shirokova N, Niggli E. Pathways of abnormal stress-induced Ca2+ influx intodystrophic mdx cardiomyocytes. Cell Calcium 2009; 46: 114-21.
19. Ramaciotti C, Iannaccone ST, Scott WA. Myocardial cell damagein Duchenne muscular dystrophy. Pediatr Cardiol 2003; 24: 503-6.
20. Frankel KA, Rosser RJ. The pathology of the heart in progressivemuscular dystrophy: epimyocardial fibrosis. Hum Pathol 1976;7:375-86.
21. Kaspar RW, Allen HD, Montanaro F. Current understanding andmanagement of dilated cardiomyopathy in Duchenne and Beckermuscular dystrophy. J Am Acad Nurse Pract 2009; 21: 241-9.
22. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptidesin cardiovascular diseases. Congest Heart Fail 2004;10: 1-30.
23. Thrush PT, Allen HD, Viollet L, Mendell JR. Re-examination ofthe electrocardiogram in boys with Duchenne muscular dystrophyand correlation with its dilated cardiomyopathy. Am J Cardiol2009; 103: 262-5.
24. Muntoni F. Cardiomyopathy in muscular dystrophies. Curr OpinNeurol 2003; 16: 577-83.
25. D'Orsogna L, O'Shea JP, Miller G. Cardiomyopathy of Duchennemuscular dystrophy. Pediatr Cardiol 1988; 9: 205-13.
26. Kirchmann C, Kececioglu D, Korinthenberg R, Dittrich S. Echocardiographicand electrocardiographic findings of cardiomyopathyin Duchenne and Becker-Kiener muscular dystrophies. PediatrCardiol 2005; 26: 66-72.
27. Mori K, Hayabuchi Y, Inoue M, et al. Myocardial strain imagingfor early detection of cardiac involvement in patients withDuchenne's progressive muscular dystrophy. Echocardiography2007; 24: 598-608.
28. Valentine BA, Cummings JF, Cooper BJ. Development ofDuchenne-type cardiomyopathy. Morphologic studies in a caninemodel. Am J Pathol 1989; 135: 671-8.
29. Anderson B. Echocardiography: The normal examination andechocardiographic measurement. Manly, Queensland, Australia:MGA Graphics 2007.
30. Tani LY, Minich LL, Williams RV, Shaddy RE. Ventricular remodelingin children with left ventricular dysfunction secondary tovarious cardiomyopathies. Am J Cardiol 2005; 96: 1157-61.
31. Oguz D, Olgunturk R, Gucuyener K, Acikgoz GV, Tunaoglu FS. Acomparison between MUGA and echocardiography in patients withmuscular dystrophy in the early detection of cardiac involvement. Pediatr Cardiol 1998; 19: 150-4.
32. Mavrogeni S, Tzelepis GE, Athanasopoulos G, et al. Cardiac andsternocleidomastoid muscle involvement in Duchenne musculardystrophy: an MRI study. Chest 2005; 127: 143-8.
33. Maisel A. Algorithms for using B-type natriuretic peptide levels inthe diagnosis and management of congestive heart failure. CritPathw Cardiol 2002; 1: 67-73.
34. Silver MA, Rosendorff C, Berkowitz R, Peacock WF. Current andemerging issues with B-type natriuretic peptide. Roundtable discussion. Congest Heart Fail 2005; 11: 212-4.
35. Silver MA. The natriuretic peptide system: kidney and cardiovasculareffects. Curr Opin Nephrol Hypertens 2006; 15: 14-21.
36. Mori K, Manabe T, Nii M, Hayabuchi Y, Kuroda Y, Tatara K. Plasma levels of natriuretic peptide and echocardiographic parametersin patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol 2002; 23: 160-6.
37. Bushby K, Muntoni F, Bourke JP. 107th ENMC internationalworkshop: the management of cardiac involvement in musculardystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13: 166-72.
38. Weber KT. Infarcted hearts of mice and men. Cardiovasc Res1999; 41: 506-8.
39. Weber KT. Fibrosis and hypertensive heart disease. Curr OpinCardiol 2000; 15: 264-72.
40. Weber KT. Fibrosis in hypertensive heart disease: focus on cardiacfibroblasts. J Hypertens 2004; 22: 47-50.
41. Bernal J, Pitta SR, Thatai D. Role of the renin-angiotensinaldosteronesystem in diastolic heart failure: potential for pharmacologicintervention. Am J Cardiovasc Drugs 2006; 6: 373-81.
42. Jefferies JL, Eidem BW, Belmont JW et al. Genetic predictors andremodeling of dilated cardiomyopathy in muscular dystrophy. Circulation2005; 112: 2799-804.
43. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, BecaneHM. Effect of perindopril on the onset and progression of leftventricular dysfunction in Duchenne muscular dystrophy. J AmColl Cardiol 2005;45: 855-7.
44. Ramaciotti C, Heistein LC, Coursey M, et al. Left ventricular functionand response to enalapril in patients with duchenne musculardystrophy during the second decade of life. Am J Cardiol 2006; 98:825-7.
45. Dick DJ, Gardner-Medwin D, Gates PG, Gibson M, Simpson JM, Walls TJ. A trial of flunarizine in the treatment of Duchenne musculardystrophy. Muscle Nerve 1986; 9: 349-54.
46. Moxley RT, III, Brooke MH, Fenichel GM, et al. Clinical investigationin Duchenne dystrophy. VI. Double-blind controlled trial ofnifedipine. Muscle Nerve 1987; 10: 22-33.
47. Pernice W, Beckmann R, Ketelsen UP, et al. A double-blind placebocontrolled trial of diltiazem in Duchenne dystrophy. Klin Wochenschr1988;66: 565-70.
48. Toifl K, Presterl E, Graninger W. Ineffectiveness of diltiazem inDuchenne muscular dystrophy: a placebo-controlled double-blindstudy. Wien Klin Wochenschr 1991; 103: 232-5.
49. Barison A, Aquaro GD, Passino C, et al. Cardiac magnetic resonanceimaging and management of dilated cardiomyopathy in aDuchenne muscular dystrophy manifesting carrier. J Neurol 2009;256: 283-4.
50. Nigro G, Politano L, Passamano L, et al. Cardiac treatment inneuro-muscular diseases. Acta Myol 2006; 25: 119-23.
51. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, LevinLS. Evolution of the mdx mouse cardiomyopathy: physiologicaland morphological findings. Neuromuscul Disord 2004; 14: 491-6.
52. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, TidballJG. Cardiomyopathy in dystrophin-deficient hearts is prevented byexpression of a neuronal nitric oxide synthase transgene in themyocardium. Hum Mol Genet 2005; 14: 1921-33.
53. Danialou G, Comtois AS, Dudley R, et al. Dystrophin-deficientcardiomyocytes are abnormally vulnerable to mechanical stressinducedcontractile failure and injury. FASEB J 2001; 15: 1655-7.
54. Nakamura A, Yoshida K, Takeda S, Dohi N, Ikeda S. Progressionof dystrophic features and activation of mitogen-activated proteinkinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett 2002; 520: 18-24.
55. Yue Y, Skimming JW, Liu M, Strawn T, Duan D. Full-lengthdystrophin expression in half of the heart cells ameliorates betaisoproterenol-induced cardiomyopathy in mdx mice. Hum MolGenet 2004;13: 1669-75.
56. Bostick B, Yue Y, Lai Y, Long C, Li D, Duan D. Adeno-associatedvirus serotype-9 microdystrophin gene therapy ameliorates electrocardiographicabnormalities in mdx mice. Hum Gene Ther 2008;19: 851-6.
57. Bostick B, Yue Y, Long C, et al. Cardiac expression of a minidystrophinthat normalizes skeletal muscle force only partially restoresheart function in aged Mdx mice. Mol Ther 2009; 17: 253-61.
58. Bostick B, Yue Y, Long C, Duan D. Prevention of dystrophindeficientcardiomyopathy in twenty-one-month-old carrier mice bymosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008; 102: 121-30.
59. Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophindeficientmice as a model for Duchenne muscular dystrophy. Cell1997; 90: 717-27.
60. Deconinck N, Rafael JA, Beckers-Bleukx G, et al. Consequencesof the combined deficiency in dystrophin and utrophin on the mechanicalproperties and myosin composition of some limb and respiratorymuscles of the mouse. Neuromuscul Disord 1998; 8: 362-70.
61. Grady RM, Teng HB, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophinand dystrophin: A model for Duchenne muscular dystrophy. Cell1997; 90: 729-38.
62. Janssen PM, Hiranandani N, Mays TA, Rafael-Fortney JA. Utrophindeficiency worsens cardiac contractile dysfunction present indystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol2005; 289: H2373-H2378.
63. Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ. Enhanced expression of the alpha 7 beta 1 integrin reduces musculardystrophy and restores viability in dystrophic mice. J Cell Biol2001; 152: 1207-18.
64. Burkin DJ, Wallace GQ, Milner DJ, Chaney EJ, Mulligan JA, Kaufman SJ. Transgenic expression of {alpha}7{beta}1 integrinmaintains muscle integrity, increases regenerative capacity, promoteshypertrophy, and reduces cardiomyopathy in dystrophicmice. Am J Pathol 2005; 166: 253-63.
65. Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletalmuscle. Genes Dev 1996;10: 1173-83.
66. Megeney LA, Kablar B, Perry RL, Ying C, May L, Rudnicki MA. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 1999; 96: 220-5.
67. Kolodziejczyk SM, Walsh GS, Balazsi K, et al. Activation of JNK1contributes to dystrophic muscle pathogenesis. Curr Biol 2001; 11:1278-82.
68. Gaschen F, Burgunder JM. Changes of skeletal muscle in youngdystrophin-deficient cats: a morphological and morphometricstudy. Acta Neuropathol 2001; 101: 591-600.
69. Gaschen FP, Hoffman EP, Gorospe JR, et al. Dystrophin deficiencycauses lethal muscle hypertrophy in cats. J Neurol Sci 1992;110: 149-59.
70. Gaschen L, Lang J, Lin S, et al. Cardiomyopathy in dystrophindeficienthypertrophic feline muscular dystrophy. J Vet Intern Med1999; 13: 346-56.
71. Ishizaki M, Suga T, Kimura E, et al. Mdx respiratory impairmentfollowing fibrosis of the diaphragm. Neuromuscul Disord 2008; 18:342-8.
72. Moise NS, Valentine BA, Brown CA, et al. Duchenne's cardiomyopathyin a canine model: electrocardiographic and echocardiographicstudies. J Am Coll Cardiol 1991; 17: 812-20.
73. Valentine BA, Chandler SK, Cummings JF, Cooper BJ. In vitrocharacteristics of normal and dystrophic skeletal muscle from dogs. Am J Vet Res 1991; 52: 104-7.
74. Valentine BA, Winand NJ, Pradhan D, et al. Canine X-linkedmuscular dystrophy as an animal model of Duchenne musculardystrophy: a review. Am J Med Genet 1992; 42: 352-6.
75. Yugeta N, Urasawa N, Fujii Y, et al. Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ):electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc Disord 2006; 6: 47.
76. Koh GY, Soonpaa MH, Klug MG, et al. Stable fetal cardiomyocytegrafts in the hearts of dystrophic mice and dogs. J Clin Invest 1995;96: 2034-42.
77. Sampaolesi M, Biressi S, Tonlorenzi R, et al. Cell therapy of primarymyopathies. Arch Ital Biol 2005; 143: 235-42.
78. Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stemcells ameliorate muscle function in dystrophic dogs. Nature 200630; 444: 574-9.
79. Galvez BG, Covarello D, Tolorenzi R, et al. Human cardiacmesoangioblasts isolated from hypertrophic cardiomyopathiesare greatly reduced in proliferation and differentiation potency. Cardiovasc Res 2009; 83: 707-16.
80. Dickson G, Roberts ML, Wells DJ, Fabb SA. Recombinant microgenesand dystrophin viral vectors. Neuromuscul Disord 2002; 12Suppl 1: S40-S44.
81. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility ofdystrophin: implications for gene therapy of Duchenne musculardystrophy. Nat Med 2002; 8: 253-61.
82. Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity inthe mdx mouse heart. Circulation 2003; 108: 1626-32.
83. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophinrestoration with antisense oligonucleotide PRO051. N Engl J Med2007; 357: 2677-86.
84. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholinooligonucleotide restores dystrophin expression bodywideand improves dystrophic pathology. Nat Med 2006; 12: 175-7.
85. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS. Long-term improvement in mdx cardiomyopathy after therapy withpeptide-conjugated morpholino oligomers. Cardiovasc Res 2010;85: 434-43.
86. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustaineddystrophin expression induced by peptide-conjugated morpholinooligomers in the muscles of mdx mice. Mol Ther 2008; 16: 1624-9.
87. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorderscaused by nonsense mutations. Nature 2007; 447: 87-91.
88. Takimoto E, Champion HC, Li M, et al. Chronic inhibition ofcyclic GMP phosphodiesterase 5A prevents and reverses cardiachypertrophy. Nat Med 2005; 11: 214-22.
89. Takimoto E, Champion HC, Belardi D, et al. cGMP catabolism byphosphodiesterase 5A regulates cardiac adrenergic stimulation byNOS3-dependent mechanism. Circ Res 2005; 96: 100-9.
90. Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ, DesRC. Metabolic and signaling alterations in dystrophin-deficienthearts precede overt cardiomyopathy. J Mol Cell Cardiol 2007; 43:119-29.
91. Khairallah M, Khairallah RJ, Young ME, et al. Sildenafil andcardiomyocyte-specific cGMP signaling prevent cardiomyopathicchanges associated with dystrophin deficiency. Proc Natl Acad SciUSA 2008;105: 7028-33.
92. Khairallah RJ, Khairallah M, Gelinas R, et al. Cyclic GMP signalingin cardiomyocytes modulates fatty acid trafficking and preventstriglyceride accumulation. J Mol Cell Cardiol 2008; 45: 230-9.
93. Bernasconi P, Torchiana E, Confalonieri P, et al. Expression oftransforming growth factor-beta 1 in dystrophic patient musclescorrelates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995; 96: 1137-44.
94. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is amelioratedby pirfenidone fed in diet after the second dose in a threedosebleomycin-hamster model. Exp Lung Res 1998; 24: 119-32.
95. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone ontransforming growth factor-beta gene expression at the transcriptionallevel in bleomycin hamster model of lung fibrosis. J PharmacolExp Ther 1999; 291: 367-73.
96. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone onprocollagen gene expression at the transcriptional level in bleomycinhamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289: 211-8.
97. Park SH, Choi SY, Kim MH, et al. The TGF-beta-induced geneproduct, betaig-h3: its biological implications in peritoneal dialysis. Nephrol Dial Transplant 2008; 23: 126-35.
98. Van EC, Irwin NG, Hoey AJ. Long-term administration of pirfenidoneimproves cardiac function in mdx mice. Muscle Nerve 2006;34: 327-34.
99. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, MetzgerJM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005; 436: 1025-9.
100. Quinlan JG, Wong BL, Niemeier RT, McCullough AS, Levin L, Emanuele M. Poloxamer 188 failed to prevent exercise-inducedmembrane breakdown in mdx skeletal muscle fibers. NeuromusculDisord 2006; 16: 855-64.
101. Townsend D, Yasuda S, Metzger J. Cardiomyopathy of Duchennemuscular dystrophy: pathogenesis and prospect of membrane sealantsas a new therapeutic approach. Expert Rev Cardiovasc Ther2007; 5: 99-109.